Oppenheimer raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: